Trial record 1 of 41 for:    " February 27, 2008":" March 28, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Previous Study | Return to List | Next Study

Yoga for the Management of HIV-Metabolic Syndromes

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00627380
First received: February 28, 2008
Last updated: July 23, 2010
Last verified: July 2010
  Purpose

We are testing the safety and efficacy of a 16-wk yoga lifestyle intervention on oral glucose tolerance, fasting lipid/lipoprotein levels, body composition, cardiovascular function, quality of life, CD4+ T-cell counts and viral load in HIV-infected men and women with components of The Metabolic Syndrome. We hypothesize that a yoga lifestyle intervention will improve metabolic, anthropometric, cardiovascular disease parameters, and quality of life domains without adversely affecting immune or virologic status in people living with HIV.


Condition Intervention Phase
HIV Infections
HIV Metabolic Cardiovascular Syndrome
HIV Lipodystrophy
HIV Metabolic Syndromes
Hypertension
Behavioral: Yoga lifestyle intervention
Other: Standard of care
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Yoga for the Management of HIV-Metabolic Syndromes

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • The primary efficacy outcome is a metabolic parameter: insulin integrated area under the curve (AUC) during the oral glucose tolerance test. [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Fasting lipid/lipoprotein levels. [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Body composition: visceral and subcutaneous adipose tissue areas (VAT, SAT), trunk/limb adipose ratio. [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Cardiovascular disease risk: Framingham 10-yr CVD risk calculation [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Quality of life: SF36 MOS [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: No ]
  • Safety: CD4 count and plasma HIV RNA [ Time Frame: Baseline and week 16 ] [ Designated as safety issue: Yes ]

Enrollment: 60
Study Start Date: November 2005
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: STOC
Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
Other: Standard of care
Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
Other Name: Observation control group
Experimental: YOGA
Yoga lifestyle intervention administered by certified yoga instructor.
Behavioral: Yoga lifestyle intervention
Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
Other Names:
  • Hatha yoga
  • Ashtanga yoga

Detailed Description:

Very few safe, effective, and novel treatments for metabolic syndromes that develop in HIV-infected people exist. These metabolic syndromes may increase cardiovascular disease risk in HIV-infected people and may reduce their quantity and quality of life. Practicing a yoga lifestyle intervention may provide a safe, effective and novel therapy for HIV metabolic syndromes, but this alternative form of therapy has not been tested in HIV-infected people with metabolic syndromes. In men and women with HIV-related metabolic syndromes, we will determine:

  1. The safety of practicing a yoga lifestyle in HIV-infected people treated with HAART who are experiencing metabolic and anthropometric syndromes.
  2. To quantify the effects of practicing a yoga lifestyle on metabolic and anthropomorphic syndromes in HIV-infected people treated with HAART who are experiencing these syndromes.
  3. To quantify the effects of practicing a yoga lifestyle on cardiovascular disease (CVD) risk in HIV-infected people treated with HAART who are at increased CVD risk because of existing metabolic and anthropomorphic syndromes.
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-infected volunteers must have dyslipidemia (fasting serum LDL-cholesterol >100mg/dL, or
  • triglycerides >200mg/dL, or
  • HDL-cholesterol <40mg/dL (men) or <50mg/dL (women), or
  • impaired glucose tolerance (fasting blood glucose 100-140mg/dL or
  • fasting insulin 13-45µU/mL or 2hr glucose during the oGTT 140-200mg/dL),or
  • central adiposity (waist circumference >102 cm (40inches in men) or >88cm (35inches in women)
  • The purpose is to identify and enroll participants with a clear proatherogenic lipid profile
  • increased CVD risk
  • abdominal adiposity, and fasting glucose intolerance or insulin resistance
  • but not type 2 diabetics who have normalized their blood sugars using glucose-lowering agents. If a type 2 diabetic uses a glucose-lowering medication, but they are still insulin resistant/glucose intolerant (by above criteria), they are eligible to participate, because we are testing the added benefits of yoga therapy on a defined dysmetabolic syndrome in participants who are stable on the standard-of-care for these metabolic syndromes, and this includes glucose- and lipid-lowering agents
  • These criteria must be met, even in volunteers receiving glucose- or lipid-lowering agents, so that we enroll participants who have developed metabolic syndromes that are not normalized by traditional pharmacologic approaches
  • Volunteers receiving glucose- or lipid-lowering agents who have normalized their lipid, glucose and insulin levels below these defined limits, are not eligible to enroll.

Additional Inclusion Criteria.

  • 18-70 years old.
  • Plasma HIV RNA <15,000 copies/ml for previous 3months.
  • CD4 count >200 c/µL for previous 3 months.
  • Stable HIV RNA level and stable CD4 count for at least the past 3 months. Some HIV-infected people can accomplish this while not receiving HAART (eg. long term non-progressors) and will be included. But, most of the participants will be on a HAART regimen that includes either 2 NRTIs + NNRTI, or 2NRTIs + PI, or NRTI+NNRTI+PI
  • "Normal" blood chemistries for at least 1 month prior to enrollment:

    • platelet count >30,000/mm3
    • absolute neutrophil count >750/mm3
    • transaminases <5x the upper limit of normal
    • creatinine <3x the upper limit of normal
    • albumin >30g/L

Exclusion Criteria:

  • Chronic hepatitis B infection (HB surface antigen positive). Active hepatitis C infection (detectable Hep C RNA). Those who have cleared hepatitis B or C infection are eligible.
  • Diabetes [fasting glucose >140 mg/dL, or fasting insulin >45 µU/mL, or 2-hr glucose >200mg/dL].
  • History of diabetes mellitus that pre-dates HIV-infection. Medications or agents that regulate glucose or lipid metabolism (e.g., insulin-sensitizers, insulin-secretagogues, HMG-CoA reductase inhibitors ('statins'), fibrates, niacin) are permitted. A large percentage of ACTU subjects and ID Clinic patients receiving RTV-boosted regimens are also receiving lipid-lowering agents. Excluding them might significantly reduce the pool of potential enrollees. The glucose- or lipid-lowering agent and dose must be stable for at least 3 months prior to screening. Additionally, volunteers taking glucose-or lipid-lowering agents must still have dyslipidemia and impaired glucose tolerance criteria (above). If they are taking these agents and have 'normalized' their lipids/lipoproteins and hyperinsulinemia, then they are not eligible
  • Gestational diabetes, pregnancy, or nursing mothers. Menstruating women must have a negative urine pregnancy test within 14 days prior to DEXA testing (minor radiation exposure from DEXA). To control for potential metabolic effects of alterations in female hormones during the menstrual cycle, all menstruating women will be tested during the follicular phase.
  • Hypogonadism [total testosterone <200ng/dL (men) or <15ng/dL (women)]; thyroid disorder [TSH <0.2 or >12µIU/mL]; hypercortisolemia [morning cortisol >22µg/dL]. Replacement testosterone or thyroid hormones or human growth hormone to normalize abnormal levels is acceptable, as long as treatment has been stable, and blood testosterone, TSH or IGF-1 levels are within the normal range.
  • Unwilling or unable to attend supervised yoga sessions 3days/wk provided by Brentwood Center for Health at the Connectcare Clinic. Any condition that might be contraindicated for yoga therapy (disabling neuromuscular or musculoskeletal injury/disorder)
  • History of serious cardiovascular disease; MI, unstable angina, heart failure, congenital heart disease, coronary artery disease, resting ST-segment depression >1mm, coronary artery bypass graft, stroke, sinus tachycardia, arrhythmias, premature atrial or ventricular contractions, claudication. Bundle branch block is exclusionary because it limits the interpretability of the resting/exercise ECG. Cardiovascular contraindications to maximal exercise testing
  • Anticipated change in anti-HIV medications or other medications that affect metabolism, within the next 4months
  • Well-trained athletes (defined as >3 exercise training exposures/week; >30min regimented exercise/exposure maintained for at least the prior 4 weeks)
  • Active substance abuse (eg, alcoholism, cocaine, heroin, crack, methamphetamine, phencyclidine)
  • Active secondary infection or a significant change in chronic suppressive therapy for an opportunistic infection during 1 month prior to enrollment
  • New serious systemic infection during the 3 weeks prior to enrollment
  • Recent episode of hyperlactatemia or lactic acidosis, esp. with rapid weight loss
  • Chronic renal insufficiency/failure or other comorbid conditions (eg. cancer, COPD) that alter metabolism
  • Pancreatitis, celiac disease, or cirrhosis
  • Inadequate macronutrient or energy intake, or malabsorptive disorder as determined by the research dietician
  • Dementia or any condition that would prevent voluntary informed consent or compliance
  • Other compounds or blinded investigational new drugs that might affect metabolism or confound data interpretation (eg. RU486, interleukin therapy, or cytokine-receptor antagonist)
  • Oral glucocorticoid or corticosteroid use within the previous 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00627380

Locations
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Kevin E Yarasheski, PhD Washington University School of Medicine
  More Information

Publications:
Mondy K, Cade WT, Reeds DN, Lassa-Claxton S, Bopp C, Tucker S, Yarasheski KE. Hatha/Ashtanga yoga intervention modestly improves cardiovascular disease (CVD) risk parameters in dyslipidemic HIV+ subjects with central adiposity(abstract). Antiviral Ther. 12 (suppl 2):L47, 2007.

Responsible Party: Kevin E. Yarasheski/Principal Investigator, Washington University
ClinicalTrials.gov Identifier: NCT00627380     History of Changes
Other Study ID Numbers: R21 AT003083, R21AT003083, WU187
Study First Received: February 28, 2008
Last Updated: July 23, 2010
Health Authority: United States: Federal Government

Keywords provided by Washington University School of Medicine:
HIV
AIDS
insulin resistance
diabetes
dyslipidemia
visceral adiposity
subcutaneous adipose wasting
cardiovascular disease
hypertension
endothelial function
quality of life
Complementary Therapies

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Hypertension
Lipodystrophy
Metabolic Syndrome X
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on August 28, 2014